Cart
sales@molnova.com
Marstacimab
CAS No. 1985638-39-8
Marstacimab( —— )
Catalog No. M37307 CAS No. 1985638-39-8
Marstacimab (PF-06741086), an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody, is utilized in hemophilia research .
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 687 | In Stock |
|
| 10MG | 937 | In Stock |
|
| 25MG | 1416 | In Stock |
|
| 50MG | 1832 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMarstacimab
-
NoteResearch use only, not for human use.
-
Brief DescriptionMarstacimab (PF-06741086), an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody, is utilized in hemophilia research .
-
DescriptionMarstacimab (PF-06741086) is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody. Marstacimab can be used for the research of hemophilia.
-
In Vitro——
-
In VivoAnimal Model:Acute bleeding hemophilia A mouse modelsDosage:0.5 mg/kg Administration:Intravenous injection, 0.5 mg/kg, once, before tail clip Result:Showed no effect on the blood loss compared with control mice, but significantly reduced the blood loss with the combination of aPCC 200 U/kg.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1985638-39-8
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Patel-Hett S, et al. Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas. Haemophilia. 2019 Sep;25(5):797-806.?
molnova catalog
related products
-
Etofibrate
Etofibrate is a combination of clofibrate and niacin, used to treat hyperlipemia.
-
Sabeluzole
Sabeluzole (R-58735) has antiepileptic and cognitive enhancing effects, inhibits neurotoxin-induced tau expression and cell death.
-
5-HT2B antagonist-1
5-HT2B antagonist-1 is an orally active 5-HT2B receptor antagonist with an IC50 of 33.4 nM, suitable for studies of diseases characterized by 5-HT2B receptor signaling, such as hepatocellular carcinoma, cardiovascular disease, or gastrointestinal disease .
